ANGPTL3 and coronary artery disorder: Using results on 60,801 CAD cases and 123,504 control from the CARDIoGRAMplusC4D consortium, we found strong evidence of a genetically predicted effect for each therapeutic target on CAD risk (based on false discovery rate (FDR) < 5%) with the exception of ANGPTL3 (S2 Table and Fig 2), in keeping with prior findings [5,24–28].